Adult Dosing
Persistent or recurrent cutaneous T-cell lymphoma
- 9 or 18 mcg/kg intravenously over 30-60 minutes for 5 consecutive days every 21 days for 8 cycles
- Note: Premedicate with an antihistamine and acetaminophen prior to denileukin diftitox administration
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
- Administer therapy in a facility equipped and staffed for cardiopulmonary resuscitation as it may cause serious and fatal infusion reactions. Suspend therapy immediately if serious infusion reactions occur [US Black Box Warning]
- Carefully monitor weight, edema, blood pressure and serum albumin levels prior to initiating therapy as it may cause capillary leak syndrome resulting in death [US Black Box Warning]
- Following administration of drug, incidences of loss of visual acuity, usually with loss of color vision, with or without retinal pigment mottling has been reported [US Black Box Warning]
- Prior to initiating therapy confirm that the patient’s malignant cells express CD25
- Monitor serum albumin levels prior to the initiation of each treatment course. Suspend therapy if serum albumin levels are less than 3.0 g/dL
Caution: Use cautiously in
Pregnancy Category:C
Breastfeeding: Due to the potential for serious adverse reactions in nursing infants, manufacturer recommends discontinuation of nursing or discontinuation of drug, taking into account the importance of the drug to the mother.
